4.6 Article

Comparative genotypic and phenotypic analysis of human peripheral blood monocytes and surrogate monocyte-like cell lines commonly used in metabolic disease research

期刊

PLOS ONE
卷 13, 期 5, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0197177

关键词

-

资金

  1. Monash University
  2. Servier

向作者/读者索取更多资源

Monocyte-like cell lines (MCLCs), including THP-1, HL-60 and U-937 cells, are used routinely as surrogates for isolated human peripheral blood mononuclear cells (PBMCs). To systematically evaluate these immortalised cells and PBMCs as model systems to study inflammation relevant to the pathogenesis of type II diabetes and immuno-metabolism, we compared mRNA expression of inflammation-relevant genes, cell surface expression of cluster of differentiation (CD) markers, and chemotactic responses to inflammatory stimuli. Messenger RNA expression analysis suggested most genes were present at similar levels across all undifferentiated cells, though notably, IDO1, which encodes for indoleamine 2,3-dioxygenase and catabolises tryptophan to kynureninase (shown to be elevated in serum from diabetic patients), was not expressed in any PMA-treated MCLC, but present in GMCSF-treated PBMCs. There was little overall difference in the pattern of expression of CD markers across all cells, though absolute expression levels varied considerably and the correlation between MCLCs and PBMCs was improved upon MCLC differentiation. Functionally, THP-1 and PBMCs migrated in response to chemoattractants in a transwell assay, with varying sensitivity to MCP-1, MIP-1 alpha and LTB-4. However, despite similar gene and CD expression profiles, U-937 cells were functionally impaired as no migration was observed to any chemoattractant. Our analysis reveals that the MCLCs examined only partly replicate the genotypic and phenotypic properties of human PBMCs. To overcome such issues a universal differentiation protocol should be implemented for these cell lines, similar to those already used with isolated monocytes. Although not perfect, in our hands the THP-1 cells represent the closest, simplified surrogate model of PBMCs for study of inflammatory cell migration.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Pharmacology & Pharmacy

Multipathway In Vitro Pharmacological Characterization of Specialized Proresolving G Protein-Coupled Receptors

Jon Merlin, Julia Park, Teresa H. Vandekolk, Stewart A. Fabb, Jeanne Allinne, Roger J. Summers, Christopher J. Langmead, Darren M. Riddy

Summary: This study comprehensively shows how several natural mediators and synthetic ligands signal through three specialized proresolving mediator GPCRs using multiple ligands from different classes across four-six endpoint signaling assays. The potential of these receptors in treating specific autoimmune diseases, including rheumatoid arthritis, systemic scleroderma, and systemic lupus erythennatosus, is highlighted.

MOLECULAR PHARMACOLOGY (2022)

Article Biochemistry & Molecular Biology

Structural and functional diversity among agonist-bound states of the GLP-1 receptor

Brian P. Cary, Giuseppe Deganutti, Peishen Zhao, Tin T. Truong, Sarah J. Piper, Xinyu Liu, Matthew J. Belousoff, Radostin Danev, Patrick M. Sexton, Denise Wootten, Samuel H. Gellman

Summary: Recent advances in understanding the structures of G-protein-coupled receptors (GPCRs) have highlighted the importance of conformational flexibility in signal propagation. By studying the activation of the GLP-1 receptor, it was found that the conformational plasticity of peptide agonists plays a crucial role in determining agonist efficacy.

NATURE CHEMICAL BIOLOGY (2022)

Article Pharmacology & Pharmacy

Implications of ligand-receptor binding kinetics on GLP-1R signalling

Peishen Zhao, Tin T. Truong, Jon Merlin, Patrick M. Sexton, Denise Wootten

Summary: This study investigates the kinetics of GLP-1R activation and cAMP production mediated by peptide agonists. The results reveal a positive correlation between peptide agonist dissociation kinetics and the onset, duration, and conformational change of receptor-G protein coupling and cAMP signaling. These findings advance the understanding of molecular events that link GLP-1R ligand binding to intracellular signaling and have implications for the agonist action at other related class B1 GPCRs.

BIOCHEMICAL PHARMACOLOGY (2022)

Article Biochemistry & Molecular Biology

Structural and Molecular Determinants for Isoform Bias at Human Histamine H3 Receptor Isoforms

Sabrina N. Rahman, Daniel A. McNaught-Flores, Yara Huppelschoten, Daniel da Costa Pereira, Arthur Christopoulos, Rob Leurs, Christopher J. Langmead

Summary: The human histamine H3 receptor is expressed in the CNS and regulates the synthesis and release of histamine and neurotransmitters. It is associated with CNS disorders and its isoforms display variations in intracellular loop 3. The mechanisms of biased agonism at these isoforms remain unknown.

ACS CHEMICAL NEUROSCIENCE (2023)

Review Pharmacology & Pharmacy

Opportunities and challenges for the development of M1 muscarinic receptor positive allosteric modulators in the treatment for neurocognitive deficits

Huong T. M. Nguyen, Emma T. van der Westhuizen, Christopher J. Langmead, Andrew B. Tobin, Patrick M. Sexton, Arthur Christopoulos, Celine Valant

Summary: This review focuses on the drug discovery of M-1 receptor for the treatment of Alzheimer's disease and schizophrenia. Despite some progress, only a few drugs have reached clinical trials due to cholinergic adverse effects.

BRITISH JOURNAL OF PHARMACOLOGY (2022)

Review Endocrinology & Metabolism

New Insights into the Structure and Function of Class B1 GPCRs

Brian P. Cary, Xin Zhang, Jianjun Cao, Rachel M. Johnson, Sarah J. Piper, Elliot J. Gerrard, Denise Wootten, Patrick M. Sexton

Summary: G protein-coupled receptors (GPCRs), particularly the B1 class, play a critical role in maintaining homeostasis and are important drug targets. Recent advances in cryo-electron microscopy have provided valuable insights into the structure and dynamics of these receptors, which contribute to our understanding of their functions.

ENDOCRINE REVIEWS (2023)

Review Pharmacology & Pharmacy

Targeting muscarinic receptors for the treatment of alcohol use disorders: Opportunities and hurdles for clinical development

Leigh C. Walker, Kade L. Huckstep, Howard C. Becker, Christopher J. Langmead, Andrew J. Lawrence

Summary: Emerging evidence suggests muscarinic acetylcholine receptors are potential targets for treating alcohol use disorder. This review integrates findings from medicinal chemistry, molecular biology, addiction, and learning/cognition fields to explore the potential of muscarinic receptor ligands in treating cognitive dysfunction, motivation to consume alcohol, and relapse associated with alcohol use disorder. The dysfunctional role of cholinergic system in alcohol use disorder is discussed, along with the potential therapeutic targets of specific muscarinic receptors, particularly M-4 and M-5 receptors. The use of subtype-selective allosteric modulators is proposed as a strategy to target these receptors, and the potential repurposing of muscarinic receptor modulators for alcohol use disorder is highlighted.

BRITISH JOURNAL OF PHARMACOLOGY (2023)

Correction Biochemistry & Molecular Biology

Structural basis of efficacy-driven ligand selectivity at GPCRs (Feb, 10.1038/s41589-022-01247-5, 2023)

Alexander S. Powers, Vi Pham, Wessel A. C. Burger, Geoff Thompson, Yianni Laloudakis, Nicholas W. Barnes, Patrick M. Sexton, Steven M. Paul, Arthur Christopoulos, David M. Thal, Christian C. Felder, Celine Valant, Ron O. Dror

NATURE CHEMICAL BIOLOGY (2023)

Article Biochemistry & Molecular Biology

Structural basis of efficacy-driven ligand selectivity at GPCRs

Alexander S. Powers, Vi Pham, Wessel A. C. Burger, Geoff Thompson, Yianni Laloudakis, Patrick M. Sexton, Steven M. Paul, Arthur Christopoulos, David M. Thal, Christian C. Felder, Celine Valant, Ron O. Dror

Summary: The selectivity of a drug for target receptors is crucial but challenging when the receptors are similar. Serendipitous discovery of ligands that stimulate target receptors more strongly than closely related receptors provides a solution. This study reveals the structural basis for the efficacy-driven selectivity of xanomeline, a clinical drug candidate, between closely related muscarinic acetylcholine receptors (mAChRs), using atomic-level simulations. The results suggest strategies for rational design of ligands achieving efficacy-driven selectivity for G-protein-coupled receptors.

NATURE CHEMICAL BIOLOGY (2023)

Review Pharmacology & Pharmacy

Molecular and structural insights into the 5-HT2C receptor as a therapeutic target for substance use disorders

Maleesha Ubhayarathna, Christopher J. Langmead, Natalie A. Diepenhorst, Gregory D. Stewart

Summary: Substance use disorder is a chronic condition with limited treatment options. The serotonin 2C receptor shows potential for the treatment of SUD, and research on psychedelics has also focused on this receptor. New studies provide a basis for further exploration.

BRITISH JOURNAL OF PHARMACOLOGY (2023)

Review Pharmacology & Pharmacy

Molecular insights into orphan G protein-coupled receptors relevant to schizophrenia

Yao Lu, Cassandra J. Hatzipantelis, Christopher J. Langmead, Gregory D. Stewart

Summary: Schizophrenia treatment currently relies on outdated science, and targeting dopamine receptors has limited efficacy and side effects. Non-dopaminergic GPCR-targeting drugs show promise but have not yet been successfully developed for clinical use. Recent attention has focused on non-dopaminergic GPCR-targeting drugs, which have demonstrated efficacy in certain symptoms of schizophrenia.

BRITISH JOURNAL OF PHARMACOLOGY (2023)

Article Multidisciplinary Sciences

Xanomeline displays concomitant orthosteric and allosteric binding modes at the M4 mAChR

Wessel A. C. Burger, Vi Pham, Ziva Vuckovic, Alexander S. Powers, Jesse I. Mobbs, Yianni Laloudakis, Alisa Glukhova, Denise Wootten, Andrew B. Tobin, Patrick M. Sexton, Steven M. Paul, Christian C. Felder, Radostin Danev, Ron O. Dror, Arthur Christopoulos, Celine Valant, David M. Thal

Summary: The M4 muscarinic acetylcholine receptor is a significant drug target for the treatment of psychosis, cognition, and addiction. The clinical trial of xanomeline has shown promise in improving symptoms and the cryo-EM structure reveals the binding mechanism, providing insight into its complex pharmacology.

NATURE COMMUNICATIONS (2023)

Meeting Abstract Neurosciences

The Clinical Candidate Xanomeline Displays a Dual Orthosteric and Allosteric Binding Profile at the M4 mAChR

Wessel A. C. Burger, Vi Pham, Alexander Powers, Ziva Vuckovic, Jesse I. Mobbs, Alisa Glukhova, Denise Wootten, Andrew B. Tobin, Patrick M. Sexton, Steven M. Paul, Christian Felder, Radostin Danev, Arthur Christopoulos, Ron O. Dror, Celine Valant, David M. Thal

NEUROPSYCHOPHARMACOLOGY (2022)

Article Chemistry, Medicinal

Trace Amine-Associated Receptor 1 (TAAR1): Molecular and Clinical Insights for the Treatment of Schizophrenia and Related Comorbidities

Pramod C. Nair, Justin M. Chalker, Ross A. McKinnon, Christopher J. Langmead, Karen J. Gregory, Tarun Bastiampillai

Summary: Schizophrenia is a complex and severe mental illness. Current treatments primarily target dopamine neurotransmission and have limited effects on negative symptoms and cognitive impairments. Recent research on trace amine associated receptor-1 (TAAR1) suggests it may be a promising nondopaminergic target for treating schizophrenia and related disorders, with fewer side effects.

ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2022)

暂无数据